Recommendation of the President – Evrysdi (risdiplam)
On 18 October 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 148/2025 on the reimbursement of the medicinal product Evrysdi ((risdiplam) under the drug program “Treatment of patients with spinal muscular atrophy (ICD-10: G12.0, G12.1)”